We are excited to announce that members of the EVERSANA team have contributed to a significant publication in BMC Neurology. The study, titled “Brain volume loss in relapsing multiple sclerosis: indirect treatment comparisons of available disease-modifying therapies,” provides valuable insights into the effects of various treatments on brain volume loss (BVL) in patients with relapsing multiple sclerosis. BVL may be associated with faster disability progression for patients with MS, therefore the finding of important differences in BVL rates between various disease-modifying treatments (DMTs) could have important implications for patients, clinicians and policymakers.
Special recognition goes to our esteemed authors: from EVERSANA, along with their coauthors from the University of Buffalo, Janssen Scientific Affairs, Certara USA and the Ottawa Hospital Research Institute. Their dedication to advancing medical research and improving patient outcomes is truly inspiring. This publication underscores their commitment to excellence and their relentless pursuit of innovative solutions in the field of neurology.
Read the full publication here.
Author
Elizabeth is an Associate Director of Evidence Synthesis at EVERSANA, with six years of experience conducting literature review and indirect treatment comparison projects. She has co-authored multiple publications and assisted in compiling evidence syntheses for…
Abril is a Manager of Evidence Synthesis at EVERSANA with over five years of experience in systematic and targeted literature reviews, as well as indirect treatment comparison feasibility assessments. She has contributed to projects…
Sumeet Singh is a Senior Director at EVERSANA where he leads HEOR projects for Canadian and global pharmaceutical clients. Prior to joining EVERSANA, Sumeet held various leadership positions at the Canadian Agency for Drugs…